Secukinumab to Lower Immune Side Effects in Metastatic Melanoma Treatment

Trial details

Who runs it

Duke University

Trial code

NCT07237594

Record updated

6 November 2026

Original description

The primary objective of this study is to determine the safety and feasibility of administering an IL-17A (human IgG1κ) monoclonal antibody, (Secukinumab, Cosentyx®) to participants with metastatic melanoma who have previously received immune checkpoint inhibitor (ICI) therapy, experienced an immune related adverse event (colitis, hepatitis, skin rash, psoriatic arthritis) to ICI, and are re-initiating ICI therapy.Read full original descriptionShow less

A Feasibility Study Utilizing IL-17 Blockade to Decrease Risk of Immune Related Adverse Events

The primary objective of this study is to determine the safety and feasibility of administering an IL-17A (human IgG1κ) monoclonal antibody, (Secukinumab, Cosentyx®) to participants with metastatic melanoma who have previously received immune checkpoint inhibitor (ICI) therapy, experienced an immune related adverse event (colitis, hepatitis, skin rash, psoriatic arthritis) to ICI, and are re-initiating ICI therapy.

Inclusion: Histologically confirmed advanced metastatic melanoma; Participants of any gender who are at least 18 years of age on the day of signing informed consent; Participants must be planned or scheduled by their treating physician to receive PD-1 therapy or PD-1 plus anti LAG3 or PD-1 plus anti CTLA-4 therapy as standard of care. Patients should either be restarting the same ICI regimen which contributed to the prior toxicity or have a clinical need to escalate to doublet (combination) ICI therapy, plan for therapy should be reviewed by the PI of this study; Participant (or legally acceptable representative if applicable) provides written informed consent for the trial; Participant must have had prior treatment with ICI therapy (either PD-1 therapy or PD-1 plus anti LAG3 or PD-1 plus anti CTLA-4 therapy as standard of care) and experienced grade 2 or higher immune-related colitis, hepatitis, or skin rash leading to treatment interruption or discontinuation or requiring steroid administration (systemic or topical); Note that patients who experience more than one irAEs are eligible to participate; Adequate organ function as defined below. Standard of care labs drawn within 42 days prior to consent may be used for the purposes of determining eligibility; Absolute Neutrophil Count (ANC) ≥ 1500/µL; Platelets ≥ 100,000/µL; Hemoglobin* ≥ 9.0 g/dL or ≥ 5.6 mmol/L *Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within the previous 2 weeks; AST/ALT 2.5x upper limit of normal.

Exclusion: Known diagnosis of immunodeficiency or receiving chronic systemic steroid therapy (in doses exceeding 10 mg daily of prednisone or equivalent), or any other form of immunosuppressive therapy within 7 days prior to first research biopsy; Patients with symptomatic CNS metastases and/or carcinomatous meningitis; Patients with asymptomatic, clinically stable CNS metastases are allowed provided they do not require steroid treatment; Has not been treated with secukinumab within the last 12 months; History of prior cardiac, neurologic, ocular IRAE related to ICI; history of blistering cutaneous IRAE related to ICI; History of or active (non-infectious) pneumonitis that required steroids; Active infection requiring systemic therapy; Known history of Human Immunodeficiency Virus (HIV) infection; Known history of Hepatitis B or known active Hepatitis C virus infection. NOTE: no testing for Hepatitis B or Hepatitis C is required; Known history of active TB (Bacillus Tuberculosis); Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial; History of allogenic tissue or solid organ transplant; History of active autoimmune disease requiring systemic therapy within the past 12 months, with the exception of ICI induced irAEs; History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with subject's participation for the full duration of the study, or make it not in the best interest of the subject to participate, in the opinion of the treating physician; Uveal melanoma; Any participants known to be pregnant or breastfeeding.

ClinicalTrials.gov NCT07237594